PAFAH POLYCLONAL ANTIBODY

Catalog number: BS-1451R
Brand: Bioss Antibodies
Packing: 100 ul
Price: € 324.00
Expected delivery time: 7 days
Quantity:
IHC-P / Rabbit
Formalin-fixed and paraffin embedde...
IF(IHC-P) / Rat
Formalin-fixed and paraffin-embedde...
IHC-P / Human
Formalin-fixed and paraffin embedde...
IHC-P / Mouse
Paraformaldehyde-fixed, paraffin em...

Product specifications for - PAFAH POLYCLONAL ANTIBODY

Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: western blot, immunohistochemistry-paraffin, IF(IHC-P)
Application note: WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)
Species: Human, Mouse, Rat
Host: Rabbit
Target: PLA2G7
Target description: phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Source: KLH conjugated synthetic peptide derived from human PAFAH2
Properties: 
Purity: Purified by Protein A.
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 1ug/ul
Form supplied: Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage instructions: -20-¦C
Scientific information: 
Scientific info: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phosphol
Gene ID: 7941
Swiss prot ID: Q13093
Additional information: 
Synonyms: BS-1451R; PAFAD; PAFAH; LP-PLA2; LDL-PLA2; Platelet-activating factor acetylhydrolase; PAF acetylhydrolase; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase; Group-VIIA phospholipase A2; gVIIA-PLA2; LDL-associated phospholipase A2; LDL-PLA(2); PAF 2-acylhydrolase; PLA2G7
Wang, Gangqi, et al. "Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NF [kgr] B pathways." Scientific Reports 4 (2014). Read more
Rosing, Katharina, et al. "Everolimus Therapy Is Associated With Reduced Lipoprotein-Associated Phospholipase A 2(Lp-Pla 2) Activity And Oxidative Stress In Heart Transplant Recipients." Atherosclerosis (2013). Read more